OTCMKTS:RHHBY Roche (RHHBY) Stock Price, News & Analysis $35.44 +0.15 (+0.43%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendHeadlinesInsider TradesOwnershipShort Interest About Roche Stock (OTCMKTS:RHHBY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Roche alerts:Sign Up Key Stats Today's Range$35.39▼$35.6450-Day Range$35.13▼$40.5752-Week Range$29.20▼$42.43Volume597,900 shsAverage Volume2.07 million shsMarket CapitalizationN/AP/E RatioN/ADividend Yield2.40%Price TargetN/AConsensus RatingReduce Company OverviewRoche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.Read More… Breaking News: Tesla headed to $500… (Ad)That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. So to claim your free digital copy today, simply follow this link and enter your email address. Receive RHHBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roche and its competitors with MarketBeat's FREE daily newsletter. Email Address RHHBY Stock News HeadlinesRoche Gets FDA Approval For First Companion Diagnostic For HER2 Treatment In Biliary Tract CancerNovember 25 at 7:08 AM | markets.businessinsider.comRoche receives FDA approval for first companion diagnostic to identify patients with biliary tract cancer eligible for HER2-targeted treatment with ZIIHERANovember 25 at 1:00 AM | prnewswire.comThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…November 25, 2024 | WealthPress (Ad)Neuron23 Announces Usage of Roche's Digital Biomarker and Device in Parkinson's Disease Clinical TrialNovember 19, 2024 | businesswire.comRoche receives CE Mark for Ventana FOLR1 RxDx AssayNovember 19, 2024 | markets.businessinsider.comRoche's VENTANA FOLR1 (FOLR1-2.1) RxDx Assay Gets CE Mark In Ovarian Cancer TreatmentNovember 18, 2024 | markets.businessinsider.comRoche receives CE Mark for VENTANA FOLR1 (FOLR1-2.1) RxDx Assay as the first IHC-based companion diagnostic to identify ovarian cancer patients eligible for ELAHERENovember 18, 2024 | prnewswire.comFlare Therapeutics Announces Strategic Discovery Collaboration with Roche to Address Previously Undrugged Transcription Factor Targets in OncologyNovember 12, 2024 | prnewswire.comSee More Headlines RHHBY Stock Analysis - Frequently Asked Questions How have RHHBY shares performed this year? Roche's stock was trading at $36.23 at the beginning of the year. Since then, RHHBY shares have decreased by 2.2% and is now trading at $35.44. View the best growth stocks for 2024 here. Does Roche have any subsidiaries? The following companies are subsidiaries of Roche: Inflazome, Stratos Genomics, Promedior, Spark Therapeutics, Tusk Therapeutics, Flatiron Health, Ignyta, and others. Who are Roche's major shareholders? Roche's top institutional shareholders include Saratoga Research & Investment Management, Boston Common Asset Management LLC, OLD National Bancorp IN and Altrius Capital Management Inc. How do I buy shares of Roche? Shares of RHHBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Today11/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPersonal Services Current SymbolOTCMKTS:RHHBY CUSIPN/A CIKN/A Webwww.roche.com Phone(161) 688-1111Fax41-0-61-691-9391Employees103,605Year Founded1896Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E Ratio13.17 P/E Growth1.81Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$65.37 billion Price / SalesN/A Cash Flow$3.12 per share Price / Cash Flow11.36 Book Value$4.91 per share Price / Book7.22Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.44 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (OTCMKTS:RHHBY) was last updated on 11/25/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roche Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Roche With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RHHBY Stock Alerts